Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576.
View in:
PubMed
subject areas
Anemia
B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive
Multiple Myeloma
T-Lymphocytes
authors with profiles
Andrzej Jakubowiak